secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001193125-25-024305
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio CFO Vineet Agarwal takes temporary medical leave; CEO Ram Aiyar named interim principal financial officer
--------------------------------------------------------------------------------

- Effective Feb 11, 2025, CFO Vineet Agarwal on temporary medical leave from Korro Bio.
- CEO Ram Aiyar appointed interim principal financial officer; no additional compensation.
- Oliver Dolan, SVP Finance, appointed interim principal accounting officer.
- Dolan has served as SVP Finance since Jan 2024; previously at Unity Biotechnology, Haven Healthcare, Compass Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312525024305/0001193125-25-024305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312525024305/d892089d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-024305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer